COMPASS Pathways (CMPS) Q2 2026 earnings summary

Executive summary

• Achieved statistically significant positive primary endpoints in both pivotal Phase 3 trials for COMP360 in treatment-resistant depression (TRD), demonstrating rapid onset and durable efficacy through at least 26 weeks, with a generally well-tolerated safety profile.

• NDA rolling submission to the FDA is underway, with completion expected in Q4 2026 and potential for accelerated approval and U.S. launch in H1 2027, pending regulatory and DEA rescheduling.

• Advanced commercial readiness initiatives include hiring experienced leadership, forming eight strategic collaborations, payer engagement, and site preparedness.

• Strong prescriber interest, with 90% of interventional psychiatrists indicating willingness to prescribe COMP360 within the first year of launch.

• Advanced development for PTSD, with late-stage trials underway and positive Phase 2 results supporting expansion.

Financial highlights

• Cash and cash equivalents of $433.3 million as of June 30, 2026, expected to fund operations through launch and into 2028.

• Net loss of $253.8 million for Q2 2026, driven by non-cash warrant expenses and higher commercial readiness costs.

• Operating expenses rose to $52.4 million in Q2 2026, mainly due to increased general and administrative costs.

• Debt increased to $50.7 million as of June 30, 2026.

• Shareholders' equity improved to $84.5 million at June 30, 2026.

Outlook and guidance

• NDA filing expected to complete in Q4 2026, with commercial launch targeted for H1 2027, subject to FDA approval and DEA/state rescheduling.

• Cash runway expected to last into 2028, but additional funding may be needed depending on regulatory, commercial, and development milestones.

• Ongoing expansion into PTSD with Phase 2b/3 trials underway.

• Focused on disciplined execution to achieve first-pass approval and rapid market entry.

• Expenses expected to increase as commercialization and clinical programs expand.